Aly MH, Alshehri AA, Mohammed A, Almaghrabi MA, Alharbi MM. Connection between dermatomyositis and montelukast sodium use: A case report. World J Dermatol 2022; 10(2): 10-16 [DOI: 10.5314/wjd.v10.i2.10]
Corresponding Author of This Article
Murouj Adnan Almaghrabi, MBBS, Doctor, College of Medicine, Umm Al-Qura University, Al-Abdia Main Campus, 8WCQ+4RM, Makkah 24382, Saudi Arabia. murouj.a.a@gmail.com
Research Domain of This Article
Dermatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Dermatol. Sep 2, 2022; 10(2): 10-16 Published online Sep 2, 2022. doi: 10.5314/wjd.v10.i2.10
Connection between dermatomyositis and montelukast sodium use: A case report
Mohammed H Aly, Abdulrahman A Alshehri, Abdelgaffar Mohammed, Murouj Adnan Almaghrabi, Malek M Alharbi
Mohammed H Aly, Abdelgaffar Mohammed, Department of Internal Medicine, Security Forces Hospital, Makkah 21599, Saudi Arabia
Abdulrahman A Alshehri, Department of Rheumatology, Security Forces Hospital, Makkah 21599, Saudi Arabia
Murouj Adnan Almaghrabi, Malek M Alharbi, College of Medicine, Umm Al-Qura University, Makkah 24382, Saudi Arabia
Author contributions: Aly MH, Alshehri AA and Mohammed A have reviewed the literature and contributed to manuscript drafting; Almaghrabi MA analyzed and interpreted the imaging findings and contributed to manuscript drafting; Alharbi MM was responsible for the revision of the manuscript for important intellectual content; all authors issued final approval for the version to be submitted.
Informed consent statement: The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given consent for his images and other clinical information to be reported in the Journal. The patient understands that his names and initials will not be published, and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Murouj Adnan Almaghrabi, MBBS, Doctor, College of Medicine, Umm Al-Qura University, Al-Abdia Main Campus, 8WCQ+4RM, Makkah 24382, Saudi Arabia. murouj.a.a@gmail.com
Received: March 6, 2022 Peer-review started: March 6, 2022 First decision: April 13, 2022 Revised: April 22, 2022 Accepted: July 26, 2022 Article in press: July 26, 2022 Published online: September 2, 2022 Processing time: 178 Days and 6.6 Hours
Abstract
BACKGROUND
Montelukast or Singulair is a leukotriene receptor antagonist that reduces inflammation and relaxes the smooth muscles. It is known to be a safe and tolerable drug; nevertheless, it might be associated with several mild to severe adverse effects, one of which is dermatomyositis. Dermatomyositis is a rare acquired autoimmune myositis of unknown cause affecting adults and children. The literature has infrequently reported the association between dermatomyositis and montelukast use.
CASE SUMMARY
The current study reports a case of a 48-year-old black woman with a previous history of bronchial asthma and allergic rhinosinusitis who presented with typical signs and symptoms of dermatomyositis which were confirmed by investigations. Before developing dermatomyositis, the patient was prescribed montelukast for atopy and consumed the drug for five months. After administration of prednisolone, the patient had a significant improvement and is still being followed up.
CONCLUSION
Even though montelukast is widely used and believed to be a safe drug for managing several conditions, the present case report highlights the possibility of adverse effects of montelukast. Therefore, future studies with advanced study designs are highly recommended to investigate the association between dermatomyositis and montelukast use.
Core Tip: Even though montelukast is widely used and believed to be a safe drug for managing several conditions, the present case report brings to light the possibility of adverse effects of montelukast. Especially in such a rare and serious complication of montelukast, physicians must be aware of the presentation of dermatomyositis, the diagnostic modalities, and the best treatment options for the patients, as the prompt diagnosis will prevent further complications progression of the condition.
